Cargando…
Efficacy of Dupilumab in Treating Atopic Dermatitis With Recurrent Eczema Herpeticum in a Patient With DOCK8-Deficiency Hyper-IgE Syndrome: A Case Report
Dupilumab, a monoclonal antibody targeting interleukin 4 and interleukin 13, was used to successfully induce remission of chronic, disseminated eczema herpeticum in a six-year-old girl who has DOCK8-deficiency hyper-IgE syndrome. The patient was started on 200 mg of dupilumab administered once every...
Autores principales: | Johar, Reshale A, Hasanain, Afnan, Khouqeer, Yousef |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494277/ https://www.ncbi.nlm.nih.gov/pubmed/37701007 http://dx.doi.org/10.7759/cureus.43360 |
Ejemplares similares
-
An Infant With Seborrhoeic Dermatitis and Eczema Herpeticum Complicated by a Generalized Infection
por: Karpierz, Katarzyna, et al.
Publicado: (2021) -
Development of Café-Au-Lait-Macule Lesions in a Patient After Dupilumab Therapy for Atopic Dermatitis
por: Hasanain, Afnan, et al.
Publicado: (2023) -
Eczema herpeticum: A medical emergency in patients with atopic dermatitis
por: Vera-Kellet, Cristián, et al.
Publicado: (2019) -
Concurrence of Acrodermatitis Enteropathica and Eczema Herpeticum in a Child with Atopic Dermatitis
por: Satria, Budi, et al.
Publicado: (2019) -
Dupilumab for Atopic Dermatitis: The Silver Bullet We Have Been Searching for?
por: Tameez Ud Din, Ahsan, et al.
Publicado: (2020)